MedTrace Logo

China Antihypertensive Trial in Acute Ischemic Stroke

NCT01840072 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 4071

Last updated 2024-03-27

Study results available
· View outcomes & findings →

Summary

This randomized trial tests the effect of early blood pressure reduction on major disability and death among patients with acute ischemic stroke in china.

Conditions

Interventions

OTHER

Active antihypertensive treatment

Initial antihypertensive treatment with angiotensin-converting enzyme inhibitors (Enalapril) and/or calcium channel blockers as second line medication; and/or diuretics as third line medications. Based on patients' baseline BP level, the first-line medication (intravenous Enalapril) can be used alone, or in combination with second-line medication (calcium channel blocker), and third-line medication (diuretics) to achieve the target systolic BP lowering by 10% to 25% within the first 24 hours after randomization and to achieve systolic BP below 140 mm Hg and diastolic BP below 90 mm Hg and maintain this BP level afterwards during the hospitalization.

Sponsors & Collaborators

  • Soochow University

    collaborator OTHER

  • Tulane University

    lead OTHER

Principal Investigators

  • Jiang He, MD, PhD · Tulane University SPHTM

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
22 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2013-05-31
Completion
2016-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01840072 on ClinicalTrials.gov